Metrosa

Metronidazole, the active ingredient in Metrosa, is a Nitroimidazole antibiotic presented as a topical formulation for cutaneous use. It exerts antimicrobial activity against anaerobic bacteria and protozoa, making it useful for treating inflammatory skin disorders. The product is indicated for managing rosacea and acne vulgaris in adult patients, helping to reduce redness, papules and pustules associated with these conditions.

GNH USA supplies Metrosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Metrosa is used in dermatology to target bacterial and inflammatory pathways involved in specific skin disorders. - Rosacea: improves facial redness, papules and pustules by reducing the proliferation of skin‑associated anaerobic bacteria and modulating inflammatory mediators. - Acne vulgaris: helps clear inflammatory lesions and decreases the number of Propionibacterium‑acnes colonies, leading to reduced papules, pustules and overall lesion count. - Skin bacterial overgrowth: may be employed to control localized anaerobic bacterial colonisation in certain dermatologic conditions.

Metrosa may cause local skin reactions and, rarely, systemic adverse events.

Common Side Effects: - Skin irritation: mild burning, stinging or tingling sensation at the application site, usually transient. - Redness: transient erythema or mild flushing around the treated area, often resolving without intervention. - Dryness: peeling, flaking or slight scaling of the skin where the product is applied.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, severe rash or angioedema indicating hypersensitivity. - Stevens‑Johnson syndrome: rare severe reaction with extensive skin blistering, mucosal involvement and systemic symptoms. - Anaphylaxis: life‑threatening systemic hypersensitivity that may include airway compromise, requiring emergency care.

When using Metrosa, consider the following precautions to ensure safe and effective therapy. - Hypersensitivity: avoid use in patients with known allergy to metronidazole or other nitroimidazoles. - Extensive skin damage: do not apply on large open wounds, burns or compromised skin barrier. - Pregnancy: use only if the potential benefit outweighs the risk, as safety data are limited. - Pediatric use: not recommended for children unless specifically prescribed by a qualified clinician. - Concomitant alcohol: advise patients to limit alcohol intake, as systemic absorption may cause a disulfiram‑like reaction. - Store at below 25°C: keep the product in its original container, protect from moisture and direct sunlight.

Metrosa may interact with certain systemic medications and substances; monitor the following interactions.

Major Interactions (Avoid): - Oral metronidazole: concurrent use can increase systemic exposure and risk of toxicity. - Alcohol consumption: may precipitate a disulfiram‑like reaction causing flushing, nausea and tachycardia. - Warfarin: topical use may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Lithium: systemic absorption may raise lithium levels, requiring serum monitoring. - Cytochrome P450 inducers (e.g., rifampicin): may reduce metronidazole efficacy if absorbed. - Other topical antibiotics: combined use may increase local irritation.